-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and the third leading cause of cancer-related deaths worldwide
Recently, a research team published an article on the overexpression of endonuclease viii-like protein 3 (NEIL3) in HCC, suggesting that the low survival rate of hepatocellular carcinoma (HCC) patients may be related to NEIL3
The research team collected the tumor and non-tumor tissues of 202 patients with primary liver cancer who underwent hepatectomy from 2010 to 2015, randomly selected 80 pairs of tumors and matched non-tumor specimens, and used immunohistochemical staining to detect NEIL3 expression levels
The results of the study indicate that the abnormal regulation of NEIL3 is associated with poor prognosis of liver cancer.
NEIL3 mRNA overexpression is associated with decreased overall survival and progression-free survival
Compared with non-tumor tissues, NEIL3 mRNA is overexpressed in HCC
In short, the research team believes that NEIL3 is an independent prognostic marker and a new molecular target in the proliferation and progression of HCC
When developing NEIL3 inhibitors, this may be important from a therapeutic point of view.
Original source: Zhao Z, Gad H, et al.
